INSP INVESTORS: BFA Law Reminds Inspire Medical Systems, Inc. Investors with Losses to Contact the Firm Before the Imminent January 5 Securities Class Action DeadlineNovember 20, 2025 3:46 PM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - November 20, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) and certain of the Company's senior executives for s ...

Attention Long-Term Shareholders of Inspire Medical Systems, Inc. (INSP): Grabar Law Office is Investigating Claims on Your BehalfNovember 20, 2025 1:55 PM EST | Source: Grabar Law OfficePhiladelphia, Pennsylvania--(Newsfile Corp. - November 20, 2025) - Grabar Law Office is investigating claims on behalf of Inspire Medical Systems, Inc. (NYSE: INSP) shareholders. The investigation concerns whether certain officers of Inspire Medical have breached their fiduciary duties owed to the company.Curr ...

Accessibility StatementSkip Navigation NEW YORK, Nov. 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Inspire Medical Systems, Inc. (NYSE: INSP). Shareholders who purchased shares of INSP during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/inspire-medical-systems-inc-loss-su ...

Core Viewpoint - Rosen Law Firm is encouraging investors of Inspire Medical Systems, Inc. to secure legal counsel before the January 5, 2026 deadline for a class action lawsuit related to the company's stock performance during the specified class period [2][4]. Group 1: Class Action Details - The class period for the Inspire Medical Systems, Inc. stock is from August 6, 2024, to August 4, 2025, inclusive [2]. - Investors who purchased common stock during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - A class action lawsuit has already been filed, and potential lead plaintiffs must act by January 5, 2026 [4]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience [5]. - The Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions for investors [5]. Group 3: Case Allegations - The lawsuit alleges that Inspire Medical misrepresented key facts about its Inspire V sleep apnea device, including market demand and necessary steps for its launch [6]. - Defendants are accused of issuing materially false and misleading statements that led investors to believe in strong demand for the device, resulting in investor damages when the truth was revealed [6].

Core Points - Rosen Law Firm is reminding purchasers of Inspire Medical Systems, Inc. common stock about the January 5, 2026 lead plaintiff deadline for a class action lawsuit [1][3] - Investors who purchased stock during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] Company Details - The lawsuit alleges that Inspire Medical misrepresented and failed to disclose critical information regarding the Inspire V sleep apnea device, including actual market demand and necessary steps for its launch [5] - Defendants are accused of issuing materially false and misleading statements that led investors to believe in strong demand for the Inspire V device [5] Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms issuing notices may lack the necessary experience [4] - The Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions for investors [4]

Core Viewpoint - Inspire Medical Systems, Inc. is facing a class action lawsuit due to allegations of false statements regarding the launch of its new product, Inspire V, which reportedly failed to meet demand and lacked necessary preparations for a successful rollout [3][4]. Group 1: Allegations and Issues - The complaint alleges that the launch of Inspire V was poorly executed, with significant surplus inventory and reluctance from providers to adopt the new treatment [3]. - Defendants are accused of making misleading statements about the launch's success, despite failing to complete essential tasks such as training for treatment center customers and setting up necessary IT systems [3]. - Critical issues included the lack of updated claims processing software and the absence of Medicare reimbursement at the time of the product launch [3]. Group 2: Class Action Details - The class period for the lawsuit is defined as August 6, 2024, to August 4, 2025, with a deadline for shareholders to register as lead plaintiffs by January 5, 2026 [4]. - Shareholders who purchased shares during the specified timeframe are encouraged to register for the class action, which includes portfolio monitoring for case updates [4]. - Participation in the case does not incur any costs or obligations for the shareholders [4].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. for securities fraud following a significant stock drop due to alleged violations of federal securities laws [1][3]. Company Overview - Inspire Medical Systems, Inc. develops and manufactures an implantable medical device for the treatment of sleep apnea, with its latest product being the Inspire V, which received FDA approval on August 2, 2024 [4]. Allegations and Issues - The lawsuit claims that Inspire misled investors by assuring them that all necessary steps were taken for the launch of Inspire V, which was supposed to meet high demand [5]. - Contrary to these assurances, Inspire allegedly failed to prepare clinicians and payors adequately, leading to significant delays in the device's adoption and weak demand due to excess inventory of older devices [6]. Stock Performance and Impact - On August 4, 2025, Inspire announced that the launch of Inspire V would face an "elongated timeframe," resulting in a reduction of its 2025 earnings per share guidance by over 80% [7]. - Following this announcement, Inspire's stock price dropped by $42.04 per share, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8].

Group 1: Fund Performance - Summers Value Fund LP achieved a net return of 20.4% in Q3 2025, outperforming the Russell 2000 Index ETF and the Russell 2000 Value Index ETF, which returned 12.4% and 12.5% respectively [1] - Year-to-date, the fund is up 4.9% net, compared to 10.3% and 8.9% returns for the respective indexes [1] Group 2: Inspire Medical Systems, Inc. Overview - Inspire Medical Systems, Inc. focuses on minimally invasive solutions for obstructive sleep apnea, with a one-month return of 2.472% and a 52-week loss of 54.77% [2] - As of November 18, 2025, the stock closed at $83.57 per share, with a market capitalization of $2.472 billion [2] Group 3: Investment Insights on Inspire Medical Systems, Inc. - Inspire Medical Systems was identified as a key detractor in the fund's performance due to a slower-than-expected transition to its Inspire V device, leading to a full exit from the position [3] - The company reported revenue of $224.5 million in Q3 2025, marking a 10% increase from Q3 2024 [4] - Despite recognizing the potential of Inspire Medical Systems, the company believes certain AI stocks present greater upside potential and less downside risk [4]

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and certain senior executives for securities fraud following a significant stock drop due to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of Minnesota, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. - Investors have until January 5, 2026, to request to lead the case [3]. Group 2: Company Background - Inspire Medical Systems develops and manufactures an implantable medical device for treating sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Group 3: Allegations and Stock Impact - Inspire allegedly misled investors by claiming it had taken necessary steps for the launch of Inspire V, while in reality, it failed to prepare clinicians and payors, leading to delays and weak demand [5][6]. - On August 4, 2025, Inspire announced an "elongated timeframe" for the Inspire V launch and reduced its 2025 earnings per share guidance by over 80%, causing the stock price to drop by $42.04, or more than 32%, from $129.95 to $87.91 per share [7][8].

Core Viewpoint - Rosen Law Firm is encouraging investors of Inspire Medical Systems, Inc. to secure legal counsel before the January 5, 2026 deadline for a securities class action lawsuit related to the company's stock performance during the specified class period [2][4]. Group 1: Class Action Details - The class period for the lawsuit is from August 6, 2024, to August 4, 2025, during which investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3][6]. - A class action lawsuit has already been filed, and investors wishing to serve as lead plaintiffs must act by January 5, 2026 [4][8]. Group 2: Allegations Against Inspire Medical - The lawsuit alleges that Inspire Medical misrepresented and failed to disclose critical information regarding the Inspire V sleep apnea device, including its market demand and the necessary steps for its launch [6]. - Defendants are accused of issuing materially false and misleading statements that led investors to believe in strong demand for the Inspire V device, resulting in investor damages when the true situation was revealed [6]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [5]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [5].